ORLANDO — In this video from the American Academy of Ophthalmology meeting, Lejla Vajzovic, MD, FASRS, highlights a presentation on macular telangiectasia type 2.
The clinical trials on macular telangiectasia type 2 (MacTel) weighed the design and use of anatomic endpoints on OCT.
“It has shaped how we are going to use clinical trial endpoints in the future, but also now we have the very first approved cell-based therapy for MacTel 2, which is now available for all of us to use,” Vajzovic told Healio.
Vajzovic, an ophthalmologist at Duke Eye Center, also highlighted a presentation on the